Kornimate/medical-research-clean huggingface dataset:
long term brain toxicity of chemotherapy in patients treated for a bone tumorduring childhood or adolescence

Conditions: Adults Treated During Childhood or Adolescence for a Malignant Bone Tumor (Osteosarcoma and Ewing Sarcoma)

Summary: to assess the neurocognitive outcomes in patients treated with chemotherapy for a malignant bone tumor during childhood and adolescence and the factors associated with neurocognitive impairment and/or complaints


Eligibility criteria:
inclusion criteria: for study ose a and b * patients treated for a bone sarcoma: ewing or osteosarcoma * age under 19 years at initial diagnosis * treated in the pediatric oncology department of gustave for patients diagnosed between 01.01.2001 and 31.12.2010: patients alive in complete remission at least 5 years after diagnosis * treated with at least one course of hdmtx for osteosarcoma * treated without hdmtx for ewing sarcoma * time interval between the end of treatment and inclusion \>10 y * age \> 21 y at inclusion * patients with informed consent signed * patient under guardianship * affiliated to french health insurance or beneficiary of the same or equivalent for study ose- b only: * treated with at least 8 courses of hdmtx for osteosarcoma * treated without hdmtx for ewing sarcoma * patients with ewing sarcoma will have to be matched with osteosarcoma patients according to age at the time of treatment, sex, and duration of follow-up * school level equivalent of at least the end of primary school exclusion criteria: for study ose a and b * brain radiotherapy * previous relapse except those treated by local treatment without any chemotherapy * second malignancy treated with chemotherapy * high dose chemotherapy with stem cell support * non-french speaking patients * pregnant and breastfeeding women for study ose- b only: - patient deprived of his liberty by a judicial or administrative decision
wgs analysis of covid-19 positive patients

Conditions: Coronavirus Infection; COVID-19

Summary: we aim to better understand the mode of action of covid-19 in the context of its interaction with the host genome through whole-genome sequencing.


Eligibility criteria:
inclusion criteria: * ability and acceptance to provide written informed consent and fluent in english. * men or women between 18-100+ years, inclusive. * willing to comply with study procedures. * sars-cov-2 positive test result as confirmed by a rt-pcr assay with a sputum or nasopharyngeal sample (either done prior to or at the screening visit).

Keywords: covid-19 wgs viral load viral genome
rectal cancer staging using whole body mr-pet

Conditions: Rectal Cancer

Summary: the purpose of this study is to measure the diagnostic performance of whole body (wb) mr-pet for staging rectal cancer, compared with current standard of care (chest/abdominopelvic ct and rectal mri) to investigate clinical feasibility of wb mr-pet as a one-stop preoperative imaging modality in patients with rectal cancer.


Eligibility criteria:
inclusion criteria: 1. adult patients newly diagnosed with rectal cancer on colonoscopy or sigmoidoscopy, who are potentially eligible for neoadjuvant chemoradiotherapy. 2. patients who sign informed consent. exclusion criteria: 1. patients who are contraindication for cect 2. patients who are contraindication for mri/ce-mri 3. patients who are diagnosed with tis or t1 cancer after polypectomy or emr 4. patients who were already diagnosed with an active other cancers. 5. premenopausal female patients who are pregnant. 6. patients with fasting serum glucose level (\>200mg/dl) on blood glucose meter prior to wb mr-pet. 7. patients who are physically compromised to undergo wb mr-pet.
bibr 1048 in the prevention of venous thromboembolism in patients undergoing primary elective total hip replacement surgery

Conditions: Venous Thromboembolism

Summary: * to determine the therapeutic window of bibr 1048 in order to select doses for further studies in the development plan. * twice daily regimen will be tested for most dose levels and once daily administration will also be evaluated when appropriate.


Eligibility criteria:
inclusion criteria: * patients scheduled to undergo a primary elective total hip replacement * male of female being 18 years or older * patients weighing at least 40 kg * written informed consent for study participation exclusion criteria: * bleeding diathesis, constitutional or acquired coagulation disorders * major surgery or trauma (e.g. hip fracture) within the last three months. patients with previous hip fractures associated with plate revisions at any time will be excluded * cardiovascular disease including uncontrolled hypertension at time of enrolment or history of myocardial infarction within the last 6 months * any history of haemorrhagic stroke, intracranial or intraocular bleeding or cerebral ischaemic attacks * known history of deep venous thrombosis (dvt) * gastrointestinal or pulmonary bleeding within the last year * known liver disease aspartate transaminase (ast) or alanine transaminase (alt) \> 3 x uln) * known renal disease (serum creatinine \> 1.5 x uln) * use of long- term anticoagulants, antiplatelet drugs, or fibrinolytics within 7 days prior to hip replacement operation (also contraindicated during the period of prophylaxis) * women of childbearing potential * known allergy to radiopaque contrast media * known thrombocytopenia (prior platelet count below 100,000 cells/microliter) * active malignant disease * current h2 blocker or proton pump inhibitor treatment * current cytostatic treatment * treatment with an investigational drug in the past month * leg amputee * known alcohol or drug abuse
a study of atherosclerosis in patients after radiation treatment for breast cancer

Conditions: Atherosclerosis

Summary: the purpose of this study is to compare plaque burden in the coronary and carotid arteries 5 years after adjuvant radiotherapy in women with right sided breast cancer vs left sided breast cancer.

this study reviews case series of patients with a history of breast cancer treated with radiotherapy for at least five years. the study measures atherosclerosis by using coronary and carotid artery calcium scoring.

Eligibility criteria:
inclusion criteria: * women dx with ductal carcinoma in situ or breast cancer, stage 0 to stage iiic, who received conservative surgery and radiotherapy at least 5 years ago * less than or equal to age 60 exclusion criteria: * hx of coronary disease prior to tx of ductal carcinoma in situ or breast cancer

Keywords: coronary calcium scoring breast cancer patients radiation treatment
prediction of coronary artery disease based on multimodal, non-contact information with artificial intelligence

Conditions: Coronary Artery Disease

Summary: the goal of this observational study are 1) to assess the effectiveness of modalities and/or their combination of multimodal non-contact information in predicting coronary artery disease; 2) to prospectively validate the performance of the developed artificial intelligence models in predicting coronary artery disease.

this observational study aims to assess the effectiveness and potential mechanism of modalities of non-contact captured bio-physiological information, including facial rgb information, infrared thermography temperature information, gait information, and wearable device information, individually and/or in combination, in predicting coronary artery disease (cad) with artificial intelligence technology. individuals suspected of cad and referred for evaluation will be invited to participate in the current study for analyzing the non-contact information and association with underlying cad status, in order to establish the most efficient artificial intelligence modeling strategy, and prospectively validate the predictive performance of the developed artificial intelligence models for cad prediction.

Eligibility criteria:
inclusion criteria: * suspected individuals referred to for coronary angiography or coronary computer tomography angiography. exclusion criteria: * prior percutaneous coronary intervention (pci) * prior coronary artery bypass graft (cabg) * undergoing confirmatory coronary evaluation as pre-operation routines for other cardiac diseases * with artificial body alteration (e.g. cosmetic surgery, facial trauma, or make-up) that may affect the non-contact information of study interest * age less than 18 years old * other circumstances that prevent participants from cooperating with the study process * decline to consent for study participation
the evaluation of the effectiveness of febrile seizure training given to parents

Conditions: Febrile Convulsion

Summary: objective: the aim of this study was to evaluate the effectiveness of a video-based educational intervention delivered via qr code to parents of hospitalized children aged 6 months to 5 years-an age group in which febrile seizures are most commonly observed.

method: this study will be designed as a randomized controlled trial. the study population will consist of parents of children aged between 6 months and 5 years who are hospitalized in the pediatric wards of kdz. eregli state hospital during the data collection period (september 1, 2024 - september 1, 2025). the sample will include 100 parents-50 in the intervention group and 50 in the control group-who meet the inclusion criteria. eligibility criteria for sampling; the child must have been hospitalized. the child must be between 6 months and 5 years of age. the parent must be able to speak and understand turkish. the parent must agree to participate in the study data collection: between september 1, 2024, and september 1, 2025, the "child and parent introductory information form" and the "febrile convulsion knowledge level scale for parents/caregivers" will be completed by participants who meet the eligibility criteria. no educational session or brochure will be provided to the control group. in the intervention group, after completing the "child and parent introductory information form " and the "febrile convulsion knowledge level scale for parents/caregivers", participants will be shown the educational brochure and granted access to the video training via the qr code included in the brochure. at the end of the training, the "febrile convulsion knowledge level scale for parents/caregivers" will be administered again. the brochure used in the training will be distributed to all participants in the intervention group. four weeks after the training, participants in the intervention group will be contacted again, and their data will be recollected using the same scale to assess knowledge retention and the long-term effectiveness of the training. similarly, in the control group, the "febrile convulsion knowledge level scale for parents/caregivers "will be re-administered four weeks after the initial data collection. data analysis: the data will be analyzed using the spss version 27.0 software.

Eligibility criteria:
inclusion criteria: the child has been hospitalized. the child is between 6 months and 5 years old. the parent can speak and understand turkish. the parent agrees to participate in the study. exclusion criteria: the child has not been hospitalized. the child is younger than 6 months. the child is older than 5 years. the parent or legal guardian cannot speak or understand turkish. the parent does not agree to participate in the study.

Keywords: febrile convulsion, fever, education, qr
the efficacy of tele rehabilitation- based task-specific training for cognitive function improvement

Conditions: Sclerosis, Multiple

Summary: "this study investigates the feasibility of tele-rehabilitation combined with targeted training for cognitive enhancement in individuals with multiple sclerosis (ms). multiple sclerosis (ms) is a chronic illness that affects the central nervous system, often resulting in cognitive impairments that significantly impact quality of life. tele-restoration provides an accessible and effective method for delivering therapeutic interventions, particularly beneficial for those with mobility limitations.

the study was a randomized controlled trial with multiple sclerosis patients divided into two groups: one receiving tele-rehabilitation-based task-specific training and the other receiving conventional care. the mediation group participated in structured cognitive training sessions conducted using a tele-rehabilitation platform, focusing on tasks designed to enhance memory, attention, and executive functions. psychological assessments were conducted during the mediation period to measure improvements.

Eligibility criteria:
inclusion criteria: * individuals with a diagnosis of ms confirmed by a neurologist. * between 18 and 65 years of age. * presence of psychosis confirmed by standardized psychometric testing. * a stable treatment environment that allows intervention. * internet access with camera and computer/tablet. * ability to understand and follow course directions. * willingness to give informed consent. exclusion criteria: * severe psychiatric co-morbidities affecting cognitive function. * concurrent intervention with other psychological rehabilitation programs. * lack of availability or use of technology necessary for tele-rehabilitation. * further research interventions. * unstable medical condition
white fish for cardiovascular risk factors in patients with metabolic syndrome: the wish-care study

Conditions: Cardiovascular Risk Factors; Metabolic Syndrome

Summary: the investigators performed this study to evaluate the efficacy of regular ingestion of white fish to reduce cardiovascular risk factors in patients with the metabolic syndrome, compared to a diet with no fish or seafood at all.

this study was designed as a randomized cross-over multicenter clinical trial with participating centers from the ciber de fisiopatología de la obesidad y nutrición (ciberobn), coordinated by the hospital universitario ramón y cajal, madrid. the investigators included adult patients with the metabolic syndrome as defined by the third report of the national cholesterol education program, adult treatment panel iii. all the subjects were caucasian from european ancestry. patients were randomized after the screening visit to one of two sequences: 1) sequence 1 to receive fish consumption first and then no fish. the individuals randomized to this arm continued with their previous alimentary habits, avoiding any significant nutritional imbalance, and with an ingestion of 7 serves of hake (each serve consisted of 100g of frozen namibia hake, pescanova s.a., pontevedra, spain) per week for a period of 8 weeks. afterwards they continued for another 8 weeks with the same diet except for the avoidance of fish and any other seafood; 2) sequence 2 for which they started with their previous alimentary habits, avoiding any significant nutritional imbalance, as well as any fish or seafood for the first 8 weeks. afterwards they were changed to the same diet but with 7 serves of hake per week.

Eligibility criteria:
inclusion criteria: * we included adult patients with the metabolic syndrome as defined by the third report of the national cholesterol education program, adult treatment panel iii. exclusion criteria: * fish allergy and positive antibodies to anisakis spp. * morbid obesity with bmi ≥40kg/m2. * chronic renal failure. * chronic psychopathy. * neoplasia. * refusal to participate in the study.

Keywords: white fish metabolic syndrome cardiovascular risk
effect of a goat milk-based infant formula on gastrointestinal and other symptoms and health-related quality of life.

Conditions: Infant Nutrition Disorders; Gastrointestinal Diseases

Summary: in this trial, the investigators aim to assess impact of goat milk-based infant formula on the severity and frequency of gastrointestinal symptoms, as well as other associated symptoms, and the health-related quality of life in infants exhibiting symptoms possibly related to cow's milk, compared to a cow milk-based formula.

gastrointestinal symptoms are frequent in the first 6 months of life in otherwise healthy infants fed cow milk-based infant formulas (cmf). in management special infant formulas may be considered, although none is routinely recommended. goat milk-based infant formulas (gmf) have shown promising effects on digestion and increased gastric emptying in several in vitro studies. in this trial, a total of 158 participants at age 14 to 90 days, who exhibit gastrointestinal and/or other symptoms associated with cmf consumption, as assessed with the cow's milk-related symptom score (comiss) between 6 and 10 will be randomly allocated to gmf or cmf for four weeks. the primary outcome will be the proportion of infants showing a reduction of at least 4 points in comiss following the four-week intervention period.

Eligibility criteria:
inclusion criteria: * healthy term infants with a gestational age between 37 and 42 weeks. * infants who have received cow's milk infant formula for at least 7 consecutive days. * exclusive formula feeding. * cow's milk-related symptoms score (comiss) value at baseline between ≥6 and \<10. exclusion criteria: * exclusive or partial breastfeeding (or feeding human milk) * introduced to solid food/supplementary feeding * any congenital or chronic condition * previous or present gastrointestinal illness or malformation that could interfere with study parameters * diagnosed cow's milk allergy * receiving medication with regard to functional gastrointestinal disorders (i.e., reflux medication) * sibling already participating in this study, and/or participating in another clinical trial.

Keywords: goat milk infant formula nutrition
vitamin d substitution during winter time

Conditions: Vitamin D Substitution

Summary: the purpose of this study is to confirm anticipated substitution dose of the vitamin d for sustained blood level during winter time in patients with inflammatory bowel diseases (ibd)

vitamin d substitution is widely recommended. suggested substitution doses are increasing over the time. no exact body requirement is known for patients with ibd at present. aim of the study was to confirm substitution dose obtained from model.

Eligibility criteria:
inclusion criteria: * subjects with inflammatory bowel disease exclusion criteria: * liver disease * renal disease * hypercalcemia * hyperparathyreoidism * chronic pancreatitis * concomitant vitamin d medication * pregnancy * sarcoidosis * malignancy * inability to obtain valid data from subject

Keywords: vitamin d inflammatory bowel diseases
study of aro-apoc3 in adults with mixed dyslipidemia

Conditions: Mixed Dyslipidemia

Summary: participants who have met all protocol eligibility criteria will be randomly assigned to treatment (aro-apoc3 or placebo) in a double-blind fashion and will be evaluted for safety and efficacy over 48 weeks. participants will be counseled to remain on a specified diet throughout the study, as recommended by the investigator in accordance with local standard of care. after week 48, participants will be eligible and invited to consent and continue in an open-label extension study. all placebo participants who opt to continue will switch to active drug (aro-apoc3) during the extension study.


Eligibility criteria:
inclusion criteria: based on medical history, evidence of tg ≥ 150 mg/dl but ≤ 499 mg/dl on more than one occasion * fasting levels at screening of non-hdl-c ≥ 100 mg/dl or ldl-c ≥ 70 mg/dl after at least 4 weeks of stable diet and stable optimal statin therapy * mean fasting tg ≥ 150 mg/dl and ≤ 499 mg/dl during screening collected at two separate and consecutive visits and at least 7 days apart and not more than 14 days apart * willing to follow diet counseling as per investigator judgment based on local standard of care * participants of childbearing potential (males \& females) must use highly-effective contraception during the study and for at least 24 weeks following the last dose of study medication. males must not donate sperm and females must ot donate eggs during the study and for at least 24 weeks following the last dose of study medication. * women of childbearing potential must have a negative pregnancy test at screening and cannot be breastfeeding * women of childbearing potential on hormonal contraceptives must be stable on the medication for ≥ 2 menstrual cycles prior to day 1 * willing to provide written informed consent and to comply with study requirements exclusion criteria: * current use or use within 365 days from day 1 of any hepatocyte targeted sirna or antisense oligonucleotide molecule * active pancreatitis within 12 weeks prior to day 1 * any planned bariatric surgery or similar procedures to induce weight loss from consent through end of study * acute coronary syndrome event within 24 weeks of day 1 * major surgery within 12 weeks of day 1 * planned coronary intervention (e.g., stent placement or heart bypass) during the study * new york heart association class ii, iii or iv heart failure or last known ejection fraction of \<30% * uncontrolled hypertension * known history of human immunodeficiency virus (hiv) infection, seropositive for hepatitis b (hbv), seropositive for hepatitis c (hcv) * uncontrolled hypothyroidism or hyperthyroidism * hemorrhagic stroke within 24 weeks of day 1 * history of bleeding diathesis or coagulopathy * current diagnosis of nephrotic syndrome * systemic use of corticosteroids or anabolic steroids within 4 weeks prior to day 1 or planned use during the study * malignancy within the last 2 years prior to date of consent requiring systemic treatment (some exceptions apply) note: additional inclusion/exclusion criteria may apply per protocol
percutaneous removal and margin ablation for breast cancer

Conditions: Breast Cancer

Summary: we hypothesize that radiofrequency ablation after single-insertion image guided vacuum assisted biopsy (iveb) can be used to achieve negative margins in small unicentric breast cancers (≤1.5 cm).

using the mammotome breast biopsy system (iveb) in conjunction with mri to predict extent of disease, ultrasound to direct removal of the tumor, touch preparation cytology for diagnosis, and ablation of margins using radiofrequency ablation (rfa), we propose to develop a comprehensive system for same-day diagnosis and treatment of patients with small breast lesions.

Eligibility criteria:
inclusion criteria: * female, 18 to 90 years of age * non-pregnant, not breastfeeding * pre-study documentation of: * size ≤1.5 cm cancer successfully removed by us-guided iveb within 30 days of registration * uni-centricity, unilateral cancer by radiology (mammogram and mri) * location of abnormality \> 1 cm from the skin * ductal carcinoma, invasive (grade i-iii) or in-situ * no palpable axillary or supraclavicular lymph nodes * good general health * zubrod performance status of 0, 1, or 2 * if prior non-breast malignancy, must have 5 year disease-free survival * no prior chemotherapy * hormonal therapy must be stopped * therapy with tamoxifen must have been of 14 days or less duration exclusion criteria: * subjects less than 18 years of age or greater than 90 years of age * pregnant or breastfeeding * male * prior breast biopsy affected breast * breast implants * multicentric disease, bilateral disease * residual disease after iveb of \> 1cm on mri * lesions \> 1.5 cm in diameter * lesions \< 1 cm from skin surface * previous radiation therapy to the breast

Keywords: image guided vacuum assisted biopsy radiofrequency ablation breast conservation therapy mastectomy mri